放射治疗有可能成为治疗肝癌复发的新思路
Radiation Therapy May Become the New Idea for Treatment of HCC Recurrence

作者: 郑作深 :江门市中心医院,中山大学附属江门医院,肿瘤科,江门;

关键词: 肝肿瘤亚临床病灶复发放射治疗外科治疗Liver Neoplasms Subclinical Lesions Recurrence Radiotherapy Surgical Treatment

摘要:

聚焦肝癌高复发率的世界难题,怎么办?本文提出放疗有可能成为治疗肝癌复发的新思路,癌周亚临床病灶是导致肝癌复发的主要根源,肝癌合理治疗应包括主癌灶和癌周亚临床病灶在内的所有肿瘤组织施行全面治疗,最大程度地预防肿瘤复发,这应该是肝癌治疗的理想总目标。围绕肝癌癌周亚临床病灶分布范围的认识来讨论三维适形放疗、“改良全肝移动条野放疗”和外科切除的优缺点,利用三者各有所长,优势互补的综合治疗的新方案,有待多中心循证研究证实其治疗效果,具有一定的启发性和创新性。方案1. 小肝癌宜手术切除,术后放疗用“改良全肝移动条野放疗”30 Gy,治疗已成形的肝癌癌周亚临床病灶。方案2. 大肝癌宜术前放疗,用“改良全肝移动条野放疗”30 Gy,治疗已成形的肝癌癌周亚临床病灶,继续小野3D-CRT剂量递增至60 Gy根治主癌灶,待主癌灶缩小后,二期切除。

When focusing on high rate of liver cancer recurrence in the world, what should we do? Radiotherapy presented in this paper may become a new idea to treat liver cancer recurrence. Peritumoral subclinical lesion is the leading cause of cancer recurrence. Implementation of a comprehensive treatment of all tumor tissue including primary liver cancer and peritumoral subclinical lesions to maximize the prevention of tumor recurrence is the ideal and overall goal of treatment for liver cancer. The new comprehensive treatment method consists of three-dimensional conformal radiotherapy, “improved radiotherapy with moving split fields radiation of the whole liver” and surgical resection, which has certain Instructiveness and innovativeness. Program 1: Surgical operation is preferred for small HCC followed by ra- diotherapy with “improved radiotherapy with moving split fields radiation of the whole liver” 30 Gy. Program 2: Preop- erative radiotherapy with “improved radiotherapy with moving split fields radiation of the whole liver” 30 Gy is preferred for large HCC. It is followed by 3D-CRT dose escalation to 60 Gy to treat primary neoplasms foci. Surgical resection is performed when the primary neoplasms foci diminishes.

文章引用: 郑作深 (2013) 放射治疗有可能成为治疗肝癌复发的新思路。 世界肿瘤研究, 3, 17-23. doi: 10.12677/WJCR.2013.33004

参考文献

[1] 张思维, 郑荣寿, 李霓等.中国肝癌发病的趋势分析和预测[J].中华预防医学杂志, 2012, 46(7): 587-592.

[2] 吴孟超, 周伟平, 潘泽西. 肝癌外科治疗新挑战[J]. 传染病信息, 2012, 25(5): 257-259,263.

[3] 汤钊献. 21世纪肝癌临床研究面临的挑战[J]. 临床肝胆病杂志, 2012, 28(4): 241-241.

[4] 樊嘉, 潘奇, 史颖弘. 美国、亚太和中国肝癌共识比较[J]. 临床肝胆病杂志, 2011, 27(4): 346-348.

[5] 中华人民共和国卫生部(卫办医政发[2011] 121号). 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16(10): 929-946.

[6] 郑作深, 邹雨荷, 饶健等. 460例巨大肝癌放射治疗的技术改进[J]. 临床肿瘤学杂志, 2005, 10(5): 497-501.

[7] 郑作深. 从临床实践看移动条野放射治疗肝癌的价值[J]. 胃肠病学和肝病学杂志, 2009, 18(7): 672-677.

[8] 郑作深, 叶林, 李卓永. 肝癌转移复发的研究进展[J]. 现代生物医学进展, 2009, 9(21): 4184-4186,4082.

[9] W. P. Zhou, E. C. Lai, A. J. Li, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Annals of Surgery, 2009, 249(2): 195-202.

[10] I. S. Kim, Y. S. Lim, H. C. Lee, et al. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome. Alimentary Phar- macology & Therapeutics, 2008, 27(4): 338-345.

[11] Z. Wang, Z. Li, Y. Ji. Postoperative TACE should be recommended in the HCC treatment guidelines of the American association for the study of liver diseases. Hepatology, 2011, 54(4): 1489-1490.

[12] 秦叔逵. 治疗肝细胞癌别只盯着靶向药[N]. 健康报网医学论坛, 2013-02-04.

[13] J. V. Simone. 医学界三大真相[J]. 肿瘤时讯肿瘤时讯, 2013, 10(14): 9.

[14] M. Shi, C. Q. Zhang, Y. Q. Zhang, et a1. Micrometastases of solitary hepatoeellular carcinoma and appropriate resection mar- gin.World Journal of Surgery, 2004, 28: 376-381.

[15] 张同琳, 马少华, 修典荣等.原发性肝癌全肝切除标本的病理解剖学特征及其启示[J]. 中华外科杂志, 2010, 48(13): 964- 967.

[16] 石明, 张昌卿, 冯凯涛等.肝细胞癌周围微转移分布的研究[J].中华肿瘤杂志, 2002, 24(3): 257-260.

[17] 徐彬, 李强, 付丽等. 肝细胞癌肝内微转移的研究[J]. 中华普通外科杂志, 2006, 21(8): 577-579.

[18] 丛文铭, 董辉, 王斌等. 复发性肝癌临床病理特点与发生方式探讨[J]. 中国实用外科杂志, 2009, 29(1): 71-73.

[19] H. Nishikawa, T. Inuzuka, H. Takeda, et al. A Case of advanced hepatocellular carcinoma with portal vein tumor thrombus re- fractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Reports in Oncology, 2011, 4(2): 327-335.

[20] X. Y. Lu, T. Xi, W. Y. Lou, et al. Palhobiological features of small hapatocallalar cacinoma: Correlation between tumor size and biological behavior. Journal of Cancer Research and Clinical Oncology, 2010, 137(4): 567-575.

[21] M. Kojiro. Pathology. In: T. Livraghi, M. Makuuchi, L. Buscarini, Eds., Diagnosis and treatment of hepatocellular carcinoma. London: Greenwich Medical Media, 1997: 35.

[22] K. Uka, T. Aikata, M. Karikomi, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepato- cellular carcinoma. World Journal of Gastroenterology, 2007, 19(3): 414-420.

[23] H. Toyoda, Y. Fukuda, Y. Koyama, Y. Koyama, et al. Case report: Multiple systemic lymph node metastases from a small hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 1996, 11(10): 959-962.

[24] 李天然, 田嘉和. 肝癌PET/CT研究进展[J]. 军医进修学院, 2009, 30(2): 230-231.

[25] 扬国仁, 王晓慧. 正电子药物显像在肝癌在诊疗中的应用进展[J]. 中国医疗器械信息, 2009, 15: 4-8..

[26] ICRU. Prescribing, recording and reporting photon beam therapy. ICRU Report 50, 1993.

[27] ICRU. Prescribing, recording and reporting photon beam therapy. ICRU Report 62, 1996.

[28] 王鑫, 何少琴. 精确放疗所面对的生物学问题[J]. 中华肿瘤防治杂志, 2006, 13(10): 1-4.

[29] 夏云飞, 钱剑扬, 郑作深. 移动条野技术的放射生物学和剂量学基础及改进[J]. 癌症, 2000, 19(1): 82-85.

[30] 黄贤湛. 移动条野中平面剂量分析[J]. 基层医学论坛, 2006, 10(2): 116-117.

[31] 吴孟超, 李爱军. 应重视大肝癌的综合治疗[J]. 中华医学杂志, 2006, 86(24):1657-1689.

[32] 黄尚校, 刘敏, 梁世雄等. 283例原发性肝癌三维适形放疗的预后因素分析[J]. 中国癌症防治杂志, 2012, 4(2): 163-166.

[33] F. Mornex, N. Girard, C. Beziat, et al. Feasibility and efficacy of high dose three dimensional radiotherapy in cirrhotic patients with small size hepatocellular carcinomanon-eligible for curative therapies mature results of the French phase Ⅱ RTF 1 trial. International Journal of Radiation Oncology, Biology, Physics, 2006, 66(4): 1152-1158.

[34] M. T. Liu, S. H. Li, T. C. Chu, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited fortranscatheter arterial chemoembolization. Japanese Journal of Clinical Oncology, 2004, 34(9): 532-539.

[35] T. H. Kim, D. Y. Kim, J. W. Park, et al. Three dimensional con formal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoem bolization was ineffective or unsuitable. American Journal of Clinical Oncology, 2006, 29(6): 568-575.

[36] 蒋国梁. 原发性肝癌三维适形和调强放疗的基础和临床研究[J]. 中国工程科学, 2009,11(10): 129-136.

[37] 居小萍, 张晓青, 肖作平等. 三维适形放射治疗原发性肝癌65例疗效分析[J]. 中国肿瘤, 2007,16: 735-737.

[38] 陈光烈. 肝动脉灌注化疗结合三维适形放疗的疗效[J]. 当代医学, 2010, 18(3): 38-39.

[39] 任宝志, 钟立松, 袁建军等. 18FDG PET/CT定位三维适形放疗结合介入治疗原发性肝癌的疗效和预后分析[J]. 现代肿瘤医学, 2011,19(3): 504-507.

[40] 于金明, 袁双虎. 肿瘤放疗的发展与挑战[J]. 山东大学学报(医学版), 2011, 49(10): 48-56,66.

[41] J. Choudhury, A. J. Sanyai. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clinical Liver Disease, 2004, 8(3): 575-594.

分享
Top